Approval · Notice of Compliance 33474 · 2024
AA-MEDROXY: Notice of Compliance 33474
Issued June 20, 2024
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 33474
- Date
- June 20, 2024
- Company
- AA Pharma Inc.Toronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- Administrative: Change in Product Ownership
- Canadian reference product
- PROVERA (Pharmacia & Upjohn Inc.)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| AA-MEDROXY | 02244726 | Marketed |
| AA-MEDROXY | 02244727 | Marketed |
| AA-MEDROXY | 02277298 | Marketed |
| AA-MEDROXY | 02267640 | Marketed |
Medicinal ingredients
- MEDROXYPROGESTERONE ACETATE 2.5 MG per TAB
- MEDROXYPROGESTERONE ACETATE 5 MG per TAB
- MEDROXYPROGESTERONE ACETATE 10 MG per TAB
- MEDROXYPROGESTERONE ACETATE 100 MG per TAB